The Technical Analyst
BioCryst Pharmaceuticals [BCRX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BioCryst Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-3.88% $4.21
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 867.89 mill |
| EPS: | -1.180 |
| P/E: | -3.57 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 206.15 mill |
| Avg Daily Volume: | 3.14 mill |
| RATING 2024-04-24 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.57 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.61x |
| Company: PE -3.57 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 3.91 - 4.51 ( +/- 7.03%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-31 | Thackray Helen M. | Sell | 7 525 | Common Stock |
| 2024-02-29 | Milano Vincent | Buy | 999 | Common Stock |
| 2024-02-29 | Heggie Theresa | Buy | 999 | Common Stock |
| 2024-01-03 | Stonehouse Jon P | Sell | 20 000 | Common Stock |
| 2024-01-03 | Stonehouse Jon P | Buy | 10 000 | Common Stock |
| INSIDER POWER |
|---|
| 75.04 |
| Last 100 transactions |
| Buy: 4 343 991 | Sell: 822 588 |
Forecast:
16:00 - $4.21
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $4.21
Forecast 2: 16:00 - $4.21
Forecast 3: 16:00 - $4.21
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.21 (-3.88% ) |
| Volume | 3.81 mill |
| Avg. Vol. | 3.14 mill |
| % of Avg. Vol | 121.26 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BCRX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $5.31 | N/A | Active |
|---|
BCRX
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Last 10 Buy Signals
Latest Press Releases
2024-04-22 07:00:00 - Press Release
Biocryst To Report First Quarter 2024 Financial Results On May 6
Research triangle park, n.c., april 22, 2024 (globe newswire) -- biocryst pharmaceuticals, inc. (nasdaq: bcrx) today announced that the company will report its first quarter 2024 financial results on monday, may 6, 2024.
2024-04-17 04:30:00 - Press Release
Biocryst Announces Approval Of Orladeyo® (berotralstat) By The Brazilian Health Regulatory Agency
Research triangle park, n.c., april 17, 2024 (globe newswire) -- biocryst pharmaceuticals, inc. (nasdaq: bcrx) today announced that the brazilian health regulatory agency (anvisa) has granted approval for oral, once-daily orladeyo® (berotralstat) for the prophylaxis of hereditary angioedema (hae) attacks in adults and pediatric patients 12 years of age or older.
2024-04-03 07:00:00 - Press Release
Biocryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Research triangle park, n.c., april 03, 2024 (globe newswire) -- biocryst pharmaceuticals, inc. (nasdaq: bcrx) today announced that the compensation committee of biocryst's board of directors granted six newly-hired employees stock options to purchase an aggregate of 43,975 shares, and restricted stock units (rsus) covering an aggregate of 30,625 shares, of biocryst common stock. the options and rsus were granted as of march 29, 2024, as inducements material to each employee entering into employment with biocryst. the options and rsus were granted in accordance with nasdaq listing rule 5635(c)(4).
2024-03-25 16:01:00 - Press Release
Biocryst To Present At Upcoming Investor Conferences
Research triangle park, n.c., march 25, 2024 (globe newswire) -- biocryst pharmaceuticals, inc. (nasdaq: bcrx) today announced that the company will present at the h.c. wainwright 2nd annual autoimmune & inflammatory disease virtual conference on thursday, march 28, 2024, at 2:30 p.m. et and the 23rd annual needham virtual healthcare conference on tuesday, april 9, 2024, at 10:15 a.m. et.
2024-03-05 07:01:00 - Press Release
Biocryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Research triangle park, n.c., march 05, 2024 (globe newswire) -- biocryst pharmaceuticals, inc. (nasdaq: bcrx) today announced that the compensation committee of biocryst's board of directors granted three newly-hired employees stock options to purchase an aggregate of 16,050 shares, and restricted stock units (rsus) covering an aggregate of 11,300 shares, of biocryst common stock. the options and rsus were granted as of february 29, 2024, as inducements material to each employee entering into employment with biocryst. the options and rsus were granted in accordance with nasdaq listing rule 5635(c)(4).
Latest News
2024-03-25 16:01:00 - GlobeNewsWire
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., March 25, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024, at 2:30 p.m. ET and the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 10:15 a.m. ET.
2024-03-01 08:29:19 - InvestorPlace
Hidden Penny Gems: 7 Stocks With Triple-Digit Growth Prospects
Each of these hidden penny stock gems have the potential to provide triple digit growth to investors. Investors are forever on the lookout for Investments that can turn $1 into $2 or more.
2024-02-26 09:11:05 - Zacks Investment Research
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.38 per share a year ago.
2024-02-21 16:01:00 - GlobeNewsWire
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., Feb. 21, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the TD Cowen 44th Annual Health Care Conference in Boston on Wednesday, March 6, 2024, at 10:30 a.m. ET and the Barclays 26th Annual Global Healthcare Conference in Miami on Tuesday, March 12, 2024, at 7:30 a.m. ET.
2024-02-05 07:00:00 - GlobeNewsWire
BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
RESEARCH TRIANGLE PARK, N.C. , Feb. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present five abstracts featuring new analyses of real-world use of oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) in patients 12 years and older at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting. The meeting will take place at the Walter E. Washington Convention Center in Washington, D.C., from February 23-26, 2024.
2024-01-09 10:31:13 - Zacks Investment Research
BioCryst (BCRX) Moves 25.6% Higher: Will This Strength Last?
BioCryst (BCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
2023-12-14 18:34:06 - Seeking Alpha
BioCryst: Factor D Inhibitor Data In 2024 Should Be Watched Closely
BioCryst Pharmaceuticals, Inc. proof-of-concept data from a phase 1 study, using BCX10013 for the treatment of patients with complement-mediated disorders, is expected in 2024. Oral C2, C5, and Bifunctional inhibitor drugs are also being advanced to treat patients with complement-mediated disorders. Net revenue for Q3 of 2023 came in at $85.7 million, which was a 29.8% year-over-year increase.
2023-11-21 16:01:00 - GlobeNewsWire
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., Nov. 21, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28th in Miami at 9:35 a.m. ET and the 35th Annual Piper Sandler Healthcare Conference on Wednesday, November 29th in New York at 12:30 p.m. ET.
2023-10-27 07:00:00 - GlobeNewsWire
BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
RESEARCH TRIANGLE PARK, N.C., Oct. 27, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present two abstracts on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) in patients 12 years and older at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI). The meeting will take place at the Anaheim Convention Center in Anaheim, Calif., from November 9-13, 2023.
2023-10-19 07:00:00 - GlobeNewsWire
BioCryst to Report Third Quarter 2023 Financial Results on November 2
RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2023 financial results on Thursday, November 2, 2023.